The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Awareness is being raised about the quality of IQAI's technology, and how effective it is. twitter seems to be the preferred medium for communication. It is a quick and effective means for medical professionals to share and update their knowledge. This recent tweet suggests that I am invested in a high quality product which could play a major part in the diagnosis of, and in monitoring the effectiveness of the treatment of tumours.
https://publish.twitter.com/?query=https%3A%2F%2Ftwitter.com%2FIQAI_IB%2Fstatus%2F1476300541735190535&widget=Tweet
To think that on Friday morning I was regretting not selling my entire SYME holding during late trading on the previous afternoon. This would have yielded a profit of £5K or thereabouts. It is unlikely that I would have bought back following the 25% drop, and would have waited to see how the market opened today. I usually adopt a 3 - day rule to observe how a share price settles following a severe drop. Sometimes it recovers quickly. In my biggest holding of 14 months duration, it has taken months to recover for each successive drop. This share price of this investment is currently at a year high, and I am hopeful that it will go much higher in the near future.
Back to SYME. I have undertaken extensive research on this company prior to my initial purchase and have subsequently averaged down. The reason I did not sell last Thursday is that I believe that the share price will go considerably higher this year, once targets are met and subsequently announced to the market. The CEO has not distinguished himself, and shareholders who have taken his hyperbolic announcements at face value, and believed him, will need to hold before they return to profitability. Ultimately this investment will do well. It is best to consign the short term sellers and their venomous nonsense to the green rectangle bin. A committed investor once described this bulletin board as a nest of vipers. He wasn’t far wrong.
With apologies if this has already been discussed. It could have implications for an anti-viral treatment which responds to the symptoms from a range of viral infections.
* What is flurona? Flurona is a play on words that basically jams “flu” and “coronavirus” together. While there have been reports that an Israeli patient is the first documented case of flurona in the world, infectious disease expert Amesh A. Adalja, M.D., a senior scholar at the Johns Hopkins Center for Health Security, says that these co-infections were more common when the pandemic began because the flu was circulating more widely.
* Flurona cases aren’t common yet. There is, however concern because of a practically non-existent flu season last year, and the fact that flu is circulating more widely this year. Each virus is potentially lethal. The combination could be quite severe
* There is not a lot of data on how people deal with flurona given that it doesn’t happen often. It is unclear as to how severe it may be.
* How can you get flurona? Both the flu and COVID-19 are most commonly spread via infected droplets, and people can simply be exposed to both viruses at the same time or around the same time. It is possible to contract COVID-19 one day and the flu the next and develop flurona.
* These two viruses won’t necessarily “outcompete” each other to protect you from one when you have the other. They utilize different receptors in your body. As a result, you can get the full flu and COVID-19 experience at the same time, when you have flurona.
* What are the symptoms of flurona? Flurona won’t cause new symptoms that you wouldn’t get with one illness or the other, so you could experience any of symptoms of either condition at once.
* For the COVID-19 portion of the illness, that means you could experience the following, which include Omicron variant symptoms: Fever or chills, Cough, Shortness of breath or difficulty breathing, Fatigue, Muscle or body aches, Headache, New loss of taste or smell, Sore throat, Congestion or runny nose, Nausea or vomiting, Diarrhea.
* For the flu part of flurona, you could have any of the following symptoms: Fever or feeling feverish, Cough, Sore throat, Runny or stuffy nose, Muscle or body aches, Headaches, Fatigue, Vomiting and diarrhea (this is more common in children than adults).
* How is flurona treated? There is no specific treatment for flurona. The treatment is for the individual viruses. So, you might be prescribed oseltamivir ( a flu treatment) if it’s been within 48 hours since you developed symptoms. And, if you qualify for Pfizer's Paxlovid and Merck's molnupiravir antiviral COVID-19 pills, your doctor may give them to you or another COVID-19 treatment like monoclonal antibodies or remdesivir. It’s pretty much impossible to know on your own if you have flurona. It can also be tricky for your doctor to tell without testing you for both illnesses.
Pillow
Your argument merely applies to your own set of circumstances based on your investment decisions. It does not have wider applicability.
Not only have you misspelled my pseudonym, but you have misunderstood my comment. I was simply asking, at the time of a New Year, for a little goodwill in place of the venom that a particular investor was directing at faceless individuals on this bulletin board.
I sincerely hope that your judgement improves with future investments. Regards.
" I hope you lose all your money, you spiteful people".
I have retyped your earlier comment so that you can take note as to what you wrote. The New Year is a time for renewal, hope, and optimism. You are beginning the New Year by wishing misfortune on faceless individuals on a bulletin board. Have you thought about the fact that you will probably never meet these individuals?
For the sake of your own well being if nothing else, do try and adopt a calmer attitude when writing your comments. We should not be reading comments such as this on an investment bulletin board.
A happy and successful New Year to you , and all genuine SYME investors.
I don't have an opinion about, or an axe to grind, concerning "Org", or his incessant transformations, Dr. Who style, on this board.
I have started but rarely finished reading his longer posts on several occasions. Each time an iconic scene from a film springs to mind.
https://www.youtube.com/watch?v=-U4Pvodwm0U
Without a doubt, I am disappointed with the lack of substance in this morning’s announcement. The CEO should resign. He has had his opportunity to deliver, and has failed the company and its investors. His credibility as a business leader and a deal maker has gone.
However, I still believe in the business model, and hope that the company will either hire a new CEO, or else be taken over by a financial institution with the wherewithal to get deals over the line.
One way or another, this business will grow, although investors will need to ignore today’s background noise and, instead, reflect on Warren Buffet’s wise words.
“ The stock market is a device for transferring money from the impatient to the patient”.
I suspect that many investors will regret selling their shares at today’s prices, and in some cases at a loss!
It is so clear that a tag team, who express themselves very well, is at work on this board. Their presence is due to the fact that the share price has not continued to rise today. I am labelling them as "short-term sellers" because they are presumably acting in their own self interest through sowing seeds of doubt in inexperienced investors minds? Their purpose is to persuade the latter to sell their SYME stock - just in case of abrupt reversal in the current short-term trend? I doubt whether such altruism (spending their valuable time helping out nameless individuals by preventing them from losing their capital) exists on an investment bulletin board?
There is no other rational explanation. Surely no intelligent individuals would not choose to waste their valuable time on a bulletin board unless they had an ulterior motive? If they are short-term sellers, then their "reward" will swiftly emerge. They will be like skinny dippers, standing up, waist deep, in the sea. Then suddenly at thedrop of an RNS, the tide will go out leaving them stranded.
This is irrelevant as far as I am concerned. The company will issue a suitable preliminary analysis , and comments when it is good and ready.
Last year, I was invested both in TILS and in SNG. Fortunately for me, I opted to sell all my TILS shares when the two share prices were on par and purchased SNG shares in their place.
The primary reasons were concerned with simplicity and communication. I readily understood everything an investor needs to know as regard's Synairgen's product. Tiziana Life Sciences's offering was complex and it was too difficult, at the time, for me to assess the company's potential. Likewise, Synairgen's communications to investors were clear, concise and unequivocal. Tiziana Life Science's proposals on the other hand were complex and more open to misinterpretation.
Consequently, it matters not to me which side of the New Year that Synairgen will communicate preliminary comments on the Sprinter data. I know from experience that the data will be thoroughly analysed, and the findings will be communicated in a format that will leave investors with little doubt as to the outcome of the trial. I remain confident, as has been the case for well over a year, that the results will turn out well, and that the company has a positive future, unless a large pharmaceutical company has a suitably awesome buyout deal in mind?
Kind regards, and a very healthy and happy New Year to all Synairgen investors.
There is so much about IQ-AI's patented technology to attract investment, and it surprises me that the company's MCap has stagnated at its current range for so long. Its major advantages, and potential will eventually be recognised as a consequence of the accumulated data from USA hospital trusts that currently use IQ-AI's imaging technology. The forthcoming Phase I Clinical Trial launch will also serve to attract attention to the quality of what IQ-AI have on offer viz:
* The technology eliminates the need to intravenously inject contrast agent during medical imaging procedures.
* It utilises the potential of artificial intelligence to streamline workflows, enhance diagnostic quality, and improve patient safety.
* The alleviation of potential problems arising from the long-term effects of repeated Gadolinium-based contrast agent use.
(From an investor's point of view, it should be mentioned that IQ-AI's synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office).
"This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally". Trevor Brown. June 2021.
I am looking forward to Q1, 2022 when I have little doubt that Michael Schmainda, the CEO of Imaging Biometrics LLC and his team will start to unleash the awesome potential of this company, as outlined in his recent letter to shareholders.
https://www.londonstockexchange.com/news-article/IQAI/letter-to-shareholders/15191623
Genuine investors are not writing about the share price tanking. That is the realm of those who have a vested interest, for example, the short term sellers, who have already made a great deal of profit from their endeavours in recent months.
The “shorters” have had their heyday, and would be best served from deploying their techniques elsewhere. Anyone who has conducted any research will know that SYME investors are expecting imminent good news. By imminent, I mean early in Q1, 2022. There is little point in trying to name the date. It will happen when the company has reached the stage when it has something meaningful to release. Too many companies release partial news by RNS. This is usually accompanied by a pump and dump scenario. I see little value in this, although a trader with a good sense of timing could fortuitously benefit from it.
A serious investor, who is focused on a considerable gain in the long term, will play his/her hand differently. I do not foresee a linear upward path for the share price. However, I am anticipating that SYME’s share price will be considerably higher in Q2, 2022 than it is at present.
Good fortune to genuine SYME investors.
"Have the feeling it’s tipped out, I’m out now, feared the risk of no news this side of New Years. Followed by no news on opened in 2022. Think I can back in 00.01’s within a week." Nobleman.
Oh dear! This is the first post in a month from someone, who is struggling with his spelling, punctuation, and grammar. I sometimes wonder whether some of these contributions are conceived by badly programmed bots? I have added this "contributor", together with a few others today, to my green rectangle zone.
I am happy that the share price is maintaining upwardly steady progress today. I shall now return to my book - "Banking on it" by Anne Boden, the CEO and founder of Starling Bank, the UK's first digital only bank. An excellent read if you are interested in financial technology. It has plenty of relevance to this investment.
I look forward to incoming news, which will hopefully disperse the unwanted attention of the likes of the incoherent Nobleman and the persistently pessimistic BrassGemini for ever.
Thank you for sharing highland.
I read the following paragraph with great interest. Perhaps the big aspirations voiced on this board may well happen in 2022?
"As for the size of potential deals, the RBC analysts said they expect single-asset companies in mid- to late-stage clinical development valued at around $1 billion to $5 billion will be the “sweet spot” for most M&A in 2022, but added that 'we may be due for a larger blockbuster deal'. ”
Regards, and good wishes.
It is the time of year for polls, mostly for fun. Some of them focus on events that occurred during the previous year. Others attempt to predict what will follow during the next year. This online poll is in the latter category, sets out to identify which stocks are likely to succeed in 2022. It was set up by @CapitalPmh. I am proud to be substantially invested in stock no 9 on the list, and am confident about its future success. Additionally, I have a smaller investment in stock no 1, but am less certain about the outcome of that particular stock.
https://docs.google.com/spreadsheets/d/11ymAQvhNV6EDJUjW4dXYWQ5aNvWNOKqu8Cp_17YqID4/edit#gid=0
Fiction (by driftwood123):
" most hospital cases are there for other reasons and happen to test positive for covid, should all be over by March."
Facts (data.gov.uk):
1. a) 98,515 new people had a confirmed positive test result reported on 27 December 2021. b) Between 21 December 2021 and 27 December 2021, 763,295 people had a confirmed positive test result. This shows an increase of 30.5% compared to the previous 7 days.
2. a)There were 143 deaths within 28 days of a positive test for coronavirus reported on 27 December 2021. b) Between 21 December 2021 and 27 December 2021, there have been 742 deaths within 28 days of a positive coronavirus test. This shows a decrease of -5.6% compared to the previous 7 days.
Conclusion. The situation, in terms of hospitalisations and deaths remains fluid. Any individual who speculates in the fashion of driftwood123 betrays her/his lack of ability to think rationally. Alyrtnatively, he/she has an ulterior motive to contribute such vague and unsubstantiated gibberish.
There is no point whatsoever in speculating on the potential number of hospitalisations at present. There is insufficient data about the impact of the Omricon variant to produce an accurate estimate. There are a considerable number of hospital workers throughout the country, who are unable to go to work as they have contracted the latest variant; the number in London is worryingly high.
https://www.theguardian.com/world/2021/dec/17/hundreds-off-work-ill-at-leading-london-hospital-as-omicron-cases-surge
I have 7m in my trading account @ approx 0.2p, and 6m in my Stocks and Shares ISA @ 0.145p. I have set a sell order in my trading account @ 0.4p. There are no guarantees with any investment. However, if this strategy works, I will hold 6m free shares within my ISA indefinitely.
Originally I bought 1m shares @ 0.305p hoping for a quick in and out trade. This did not work out. I then started averaging down as I researched the company’s strategy . I was hoping to sell for a profit on a spike in the share price, and subsequently to buy back within my ISA. Once again things didn’t go my way, hence the current strategy.
It is possible, I suppose that I could fall flat on my face, but I doubt it. SYME, to my reckoning, is now a conviction buy. I would be more heavily invested, but most of my capital is currently invested in a company that has a Covid treatment awaiting the results of a completed Phase III trial.
Good fortune to all SYME investors. I am convinced that this investment will come good, but as is the case with any investment, there is an element of risk. Usual caveats, DYOR etc.
It adds credibility to any investment when you have a medical physicist of the calibre of Professor Schmainda involved. She is passionate about this project, and listening to her optimism regarding the quality of preliminary results, and her determination in getting through the Phase I trials, and seamlessly into Phase II indicates that there shouldn't be any delay in getting the treatment monitored by IB's technology well on its way during Q1, 2022.
https://www.mcw.edu/departments/biophysics/people/kathleen-schmainda-phd
As I have seen with other investments this year, it takes a considerable amount of time to get through the full sequence of clinical trials, but there should be an early indication, perhaps in the first half of next year as to how this procedure is progressing. My wife lost one of her oldest friends from an aggressive brain tumour this year. There will be initiatives all over the World to develop treatments for this terrible affliction, and IB's enhanced scanning technology may prove to be importand in continuously monitoring the progress of treatments.
The interview is a very positive indication of what lies ahead, to add to the recent optimistic RNSd letter from the company to outline future developments.
The company needs to flesh out the outline information with reports on trial progress, and further contract wins, and sales in order to attract market interest.
In my opinion, this company has a long way to go and we are likely to start progressing during Q1 2022. I reconsidered my strategy last weekend following comments from fellow investors on this board, and revisiting my research notes. My current sell target is 20p for a 150% profit, but that could easily change depending on what information emerges.
Agreed Sharebel,
I have thought the same thing for quite some time. However, a statement of “proof of concept” together with the JV announcement are still lacking the substance that this potentially massive initiative requires in order for its value to be reflected in the share price.
I suspect that Q1, 2022 may be the earliest possible time zone for the the company to deliver. The product probably needs to be more thoroughly developed to match up with Volz’s technology. Moreover this will need to be followed by a period of rigorous testing. Only then, will Mr. Duffin have the substance for the RNS which serious investors are anticipating.
My opinion only. Usual caveats , DYOR etc.
Regards and good wishes.